Introduction {#Sec1}
============

*Cryptosporidium* species are protozoan parasites that infect the epithelial cells of the gastrointestinal tract, causing gastrointestinal illness. Some species have zoonotic potential and their role was described in several large waterborne outbreaks worldwide \[[@CR1]--[@CR4]\]. In immunocompetent individuals, cryptosporidiosis is usually a self-limiting infection, with the most frequent symptoms being watery diarrhoea, nausea, vomiting, fever and abdominal pain, but infections may also be asymptomatic. However, severe diarrhoea and dissemination of the infection to extra-intestinal sites may occur in high-risk individuals, such as children, the elderly and immunocompromised individuals like HIV-infected persons \[[@CR5]\]. There is no effective drug available to treat cryptosporidiosis.

Complications and long-term sequelae after an episode of acute gastroenteritis of infectious aetiology have been described for *Campylobacter jejuni*, *Escherichia coli*, most serotypes of *Salmonella enterica* \[[@CR6]\], *Yersinia enterocolitica* \[[@CR7]\], *Giardia lamblia* \[[@CR8]--[@CR10]\] and norovirus \[[@CR11]\]. Besides considerable accumulated knowledge of the acute phase of cryptosporidiosis, there is growing evidence for the presence of long-term health implications following an acute episode of *Cryptosporidium* infection. In the Netherlands during 2007--2011, the burden of cryptosporidiosis expressed in disability-adjusted life years (DALY) was estimated at 75/year, but only (acute) diarrhoea was taken into account as a consequence of cryptosporidiosis \[[@CR12]\]. However, reports of relapse or persisting diarrhoea, other gastrointestinal and non-gastrointestinal symptoms up to several months or even years post-infection are documented \[[@CR13]--[@CR16]\]. To our knowledge, only four epidemiological studies have investigated sequelae of *Cryptosporidium* infection. Rehn et al. \[[@CR14]\] described the sequelae of cases involved in two cryptosporidiosis outbreaks caused by *C*. *hominis* up to 11 months after initial infection. Stiff et al. \[[@CR13]\] investigated sequelae up to 1 year in a group of patients involved in an outbreak of *C*. *parvum* infection. While Hunter et al. \[[@CR16]\] and Insulander et al. \[[@CR15]\] investigated the role of both *C*. *hominis* and *C*. *parvum* (Insulander et al. looked at more than these two species) in sequelae amongst sporadic *Cryptosporidium* cases after 2 months of infection or following them up to 36 months respectively.

In the Netherlands, sporadic cryptosporidiosis is not notifiable by law and, in routine practice, *Cryptosporidium-*positive stools are not typed to determine the species. In the second half of 2012, an excess of cryptosporidiosis cases in the Netherlands, mainly due to *C*. *hominis* infection, triggered an international alert via the European Centre for Disease Control (ECDC)'s Epidemic Intelligence Information System (EPIS) for Food- and Water-borne Diseases (FWD). In response to this alert, the United Kingdom (UK) and Germany also reported an increase in cryptosporidiosis cases \[[@CR17]\]. As no risk factors that could explain the observed increase were identified, a case-control study for sporadic cryptosporidiosis in the Dutch general population was conducted during 2013--2016 (article in preparation). This case-control study presented the opportunity to investigate possible long-term sequelae of sporadic cryptosporidiosis, including potential species-specific effects. A follow-up study was therefore conducted to determine the frequency of occurrence of several symptoms during and following an acute episode of *C*. *hominis* or *C*. *parvum* infection as compared with the period before such infection, as well as with the symptoms reported among population controls.

Methods {#Sec2}
=======

Data collection {#Sec3}
---------------

During a case-control study to identify risk factors for sporadic cryptosporidiosis in the Netherlands (article in preparation), the participating cases were also invited via email to fill in a follow-up questionnaire 4 months after the onset of the acute phase of the infection. Recruitment of cases was performed through the collaboration with 17 regional Public Health Laboratories (PHLs) that perform *Cryptosporidium* diagnosis in the Netherlands. Cases were defined as those suffering from gastrointestinal complaints 2 weeks prior to sampling and having laboratory confirmation of *Cryptosporidium* spp. infection between April 2 2013 and April 1 2016. Controls were prospectively selected from the Netherlands' population register by frequency matching for age and area of residence as done previously \[[@CR18]\]. The expected number of cases (which the controls were frequency matched to) stratified by age was calculated using historic (2010--2012) data on cryptosporidiosis obtained from the participating 17 PHLs. Each control received an invitation letter explaining the study rationale and objectives, an informed consent, a control questionnaire and a prepaid envelope to return the questionnaire and informed consent to the Dutch National Institute for Public Health and the Environment (RIVM), where this study was performed. Questions in the questionnaires focused on musculoskeletal and other commonly described symptoms potentially associated with cryptosporidiosis, i.e. abdominal pain, vomiting, loss of appetite, weight loss, diarrhoea, headache, fatigue, dizziness, eye pain and joint pain. The follow-up questionnaire also contained a detailed list of body parts to narrow down the most affected joints, if any (i.e. neck, hips, shoulders, elbows, wrist, fingers, knees, ankles, heels, toes and upper and lower back). At follow-up, cases were asked to report whether the aforementioned symptoms were present 4 months after the acute phase of *Cryptosporidium* infection, but also whether they were already present 4 months before such infection. Within the framework of the case-control study, the same symptoms were also recorded during illness for the cases, as well as for the controls, which were then included in the analysis for comparison purposes. Basic demographic information was also collected. Returned questionnaires were encoded and their data coupled with the laboratory typing results.

Data analysis {#Sec4}
-------------

The study design was case-crossover \[[@CR19], [@CR20]\], in which we compared the frequencies of each reported symptom experienced during or 4 months after the acute phase of *Cryptosporidium* infection to those experienced 4 months before the acute illness. A complete-record analysis was performed using multivariable logistic regression models to calculate adjusted odds ratios (aOR) for the occurrence of each symptom (i.e. response variables) before vs. during or after *Cryptosporidium* infection (3-level categorical predictor variable), while adjusting for age (categorised as ≤ 5, 6--12, 13--25, 26--50 and ≥ 51 years), gender, *Cryptosporidium* species (*C*. *parvum* or *C*. *hominis*), season and study year. Clustering of observations (before, during and after illness) at the patient level was accounted for using cluster-robust standard errors. In addition, we compared the frequencies of each reported symptom in the cases before, during and after illness with those reported by the controls in the case-control study. To assess *Cryptosporidium* species-specific effects on the occurrence of each symptom, analyses were also carried out separately for *C*. *hominis* and *C*. *parvum*. Additional analyses were performed in which the age group of 0--5 years was excluded, as the quality of recording detailed symptoms in young children is likely to be lower. Data on the specific joints affected among those reporting joint pain as sequela were only available for the follow-up, i.e. 4 months after illness, but not for the periods during and before illness. While cases with travel history outside of the Netherlands were excluded from the case-control study, they were retained in this follow-up study, as whether a patient was infected domestically or abroad was irrelevant for the purposes of the present study. Controls were excluded if they had diarrheal illness 2--4 weeks before completing the questionnaire. All analyses were performed using STATA 14 (StataCorp LLC, College Station, USA).

Genotyping {#Sec5}
----------

*Cryptosporidium* species was determined in all samples by using a real-time duplex PCR with dual labelled probes on a Roche LightCycler 480 apparatus using a combination of a PCR on *C*. *parvum* and a PCR developed specifically for *C*. *hominis*. The *C*. *parvum*-specific PCR targets a gene for a hypothetical protein and the *C*. *hominis* PCR targets part of the GP60 gene \[[@CR21]\].

Results {#Sec6}
=======

Of the 731 cases included in the case-control study, 443 (60%) participated in the follow-up. Participation varied over the three study years (42, 25 and 33%, respectively). After exclusion of cases with missing data, a total of 308 (42%) cases were included in the follow-up study. The median age of these cases was 26 years (range 1 to 80 years), with the age group of 13--25 years being the least represented (Fig. [1](#Fig1){ref-type="fig"}). There were more female cases (58%), regardless of the infecting species in question: *C*. *hominis* (59%) and *C*. *parvum* (58%). Overall, 70% of cases were infected with *C*. *parvum* and the rest (30%) with *C*. *hominis*; the species distribution in the follow-up study over the three study years was 15, 13 and 61% for *C*. *hominis*, and 85, 87 and 39% for *C*. *parvum*.Fig. 1Distribution of the 308 cryptosporidiosis cases by age group and gender

Table [1](#Tab1){ref-type="table"} shows the frequencies of symptom occurrence among cryptosporidiosis cases during and after illness in comparison with the period before illness. The three most commonly reported symptoms 4 months after diagnosis were, in decreasing order fatigue (50.7%), diarrhoea (41.9%) and abdominal pain (38.3%). During illness, all symptoms were more prevalent and significantly more likely to occur than in the period before illness, with symptoms like loss of appetite, vomiting, diarrhoea, weight loss and abdominal pain being the obvious result of the (severe) episode of acute gastroenteritis. Apart from loss of appetite, eye pain and vomiting, all other symptoms were also significantly more likely to occur after acute illness as compared to the period before illness (Table [1](#Tab1){ref-type="table"}). When patients were asked which symptoms got worse after the course of illness, fatigue (9%), joint pain (4%) and abdominal pain (3%) were those most commonly mentioned. Regarding joint pain, the most affected joints were the knees (19%), fingers (14%) or neck (12%) (Fig. [2](#Fig2){ref-type="fig"}), and often more than one joint was affected (67% of patients had complaints in multiple joints).Table 1Occurrence of symptoms during and 4 months following cryptosporidiosis as compared to 4 months before illness onsetSymptomsBefore illness (baseline)During illnessAfter illness*n* (%)*n* (%)aOR*p*95% CI*n* (%)aOR*p*95% CIDizziness23 (7.5)80 (26)5.130.0003.22--8.1845 (14.6)2.250.0001.46--3.47Headache44 (14.3)106 (34.4)3.490.0002.45--4.9878 (25.3)2.150.0001.57--2.93Fatigue105 (34.1)239 (77.6)7.220.0005.13--10.16156 (50.7)2.040.0001.58--2.63Weight loss37 (12.0)196 (63.6)13.580.0008.85--20.8461 (19.8)1.820.0031.23--2.70Diarrhoea101 (32.8)269 (87.3)15.710.00010.30--23.96129 (41.9)\*1.500.0051.13--2.01Loss of appetite73 (23.7)248 (80.8)16.400.00011.08--24.2791 (29.6)1.380.0550.99--1.92Abdominal pain97 (31.5)245 (79.6)9.690.0006.71--13.99118 (38.3)\*1.380.0261.04--1.83Joint pain32 (10.4)63 (20.5)2.390.0001.56--3.6652 (16.9)1.840.0011.27--2.67Eye pain11 (3.6)30 (9.8)3.130.0011.59--6.1719 (6.2)1.830.0600.97--3.45Vomiting25 (8.1)100 (32.5)5.720.0003.60--9.0921 (6.8)0.830.5170.46--1.47Number of cryptosporidiosis cases (*n*) and percentage of the total (*n* = 308) number of cryptosporidiosis cases reporting each symptom. Odds ratios (aOR) and corresponding 95% confidence intervals (CI) are adjusted for age, gender, *Cryptosporidium* species, study year and season\*No longer statistically significant when removing children under 5 years of age from the analysis: abdominal pain OR 1.32 (95% CI 0.98--1.79, *p* = 0.071), diarrhoea OR 1.30 (95% CI 0.94--1.80, *p* = 0.108)Fig. 2Proportion (%) of cases with pain in specific joints following cryptosporidiosis (*n* = 52)

Compared to the controls (Table [2](#Tab2){ref-type="table"}), all symptoms but headache, joint pain and eye pain were significantly more likely to be reported among cryptosporidiosis cases 4 months after infection, but this was also true for the period before infection (with the exceptions of dizziness, joint and eye pain). During the acute phase of infection, all symptoms were significantly more likely to be reported among cases than controls (Table [2](#Tab2){ref-type="table"}).Table 2Occurrence of symptoms 4 months before, during and 4 months after cryptosporidiosis as compared to the control groupSymptomsControls (baseline)Before illnessDuring illnessAfter illness*n* (%)*n* (%)aOR*p*95% CI*n* (%)aOR*p*95% CI*n* (%)aOR*p*95% CIDizziness106 (5.9)23 (7.5)1.570.0990.92--2.6780 (26)8.300.0005.54--12.4245 (14.6)3.370.0002.05--5.51Headache359 (20.1)44 (14.3)0.650.0280.45--0.95106 (34.4)2.340.0001.73--3.1678 (25.3)1.230.2360.87--1.75Fatigue516 (28.8)105 (34.1)1.44\*0.0111.09--1.91239 (77.6)11.530.0008.40--15.84156 (50.7)2.850.0002.12--3.83Weight loss51 (2.9)37 (12.0)4.940.0002.99--8.16196 (63.6)70.330.00045.42--108.9161 (19.8)8.500.0005.11--14.14Diarrhoea60 (3.4)101 (32.8)32.320.00019.40--53.84269 (87.3)564.120.000298.92--1064.62129 (41.9)46.070.00026.99--78.62Loss of appetite242 (13.5)73 (23.7)2.800.0001.66--3.19248 (80.8)35.540.00024.73--51.1091 (29.6)3.220.0002.28--4.56Abdominal pain432 (24.1)97 (31.5)1.580.0021.18--2.13245 (79.6)15.970.00011.46--22.27118 (38.3)2.220.0001.63--3.02Joint pain225 (12.6)32 (10.4)0.780.2620.50--1.2163 (20.5)1.970.0001.37--2.8252 (16.9)1.350.1450.90--2.04Eye pain110 (6.2)11 (3.6)0.780.4770.40--1.5430 (9.8)2.400.0001.48--3.8919 (6.2)1.320.3610.73--2.41Vomiting66 (3.7)25 (8.1)2.690.0001.58--4.57100 (32.5)15.250.00010.16--22.9021 (6.8)1.96\*0.0311.06--3.61Number (*n*) of cases or controls and percentage of the total number of cases (*n* = 308) or controls (*n* = 1790) reporting each symptom. Odds ratios (aOR) and corresponding 95% confidence intervals (CI) are adjusted for age, gender, study year and season\*No longer statistically significant when removing children under 5 years of age from the analysis: fatigue before illness OR 1.32 (95% CI 0.96--1.81, *p* = 0.085), vomiting after illness OR 1.89 (95% CI 0.82--4.36, *p* = 0.137)

When data was analysed for the two species separately (Table [3](#Tab3){ref-type="table"}), the most common symptoms 4 months after illness were the same as for both species combined (Table [1](#Tab1){ref-type="table"}**)** or when both species combined were compared to the controls **(**Table [2](#Tab2){ref-type="table"}**)**. Yet amongst cases, none of the symptoms were significantly more likely to occur when infected with *C*. *hominis* vs. *C*. *parvum*, neither before, nor during, nor after illness (Table [4](#Tab4){ref-type="table"}).Table 3Comparisons of symptom occurrence 4 months before, during and 4 months after cryptosporidiosis and in the control group according to *Cryptosporidium* speciesSymptomsControlsBefore illnessDuring illnessAfter illnessvs. controlsvs. before illnessvs. controlsvs. before illnessvs. controls*C*. *hominisn* (%)*n* (%)aOR*p*95% CI*n* (%)aOR*p*95% CIaOR*p*95% CI*n* (%)aOR*p*95% CIaOR*p*95% CI Dizziness106 (6)7 (8)2.930.0221.17--7.3722 (24)6.400.0002.57--15.9914.410.0007.01--29.6013 (14)2.480.0730.92--6.696.040.0002.77--13.19 Headache359 (20)13 (14)0.640.1840.32--1.2431 (34)3.630.0001.85--7.132.460.0011.42--4.2122 (24)2.060.0271.09--3.901.350.3080.76--2.41 Joint pain516 (29)6 (7)0.710.4570.28--1.7613 (14)2.710.0331.08--6.771.850.0870.92--3.7414 (15)3.010.0181.21--7.502.000.0491.00--3.99 Fatigue51 (3)31 (34)1.630.0540.99--2.6967 (73)5.900.0003.15--11.059.390.0005.55--15.8846 (50)2.070.0041.27--3.383.280.0002.04--5.29 Weight loss60 (3)9 (10)\*4.950.0002.03--12.1054 (59)15.440.0006.12--38.9773.770.00035.78--152.1322 (24)3.030.0051.39--6.6212.680.0006.13--26.24 Diarrhoea242 (14)38 (41)97.590.00038. 8--245.681 (88)11.810.0005.47--25.472828.90.000637.4--12,555.546 (50)1.450.1580.87--2.44111.830.00047--266.07 Loss of appetite432 (24)25 (27)2.230.0041.29--3.8676 (83)14.740.0007.43--29.2733.260.00017.78--62.2336 (39)1.770.0261.07--2.954.410.0002.63--7.42 Abdominal pain225 (13)32 (35)1.640.0530.99--2.7173 (79)9.100.0004.62--17.9313.980.0007.92--24.6842 (46)1.680.0760.95--2.972.750.0001.70--4.46 Eye pain110 (6)1 (1)0.270.2030.04--2.037 (8)9.010.0361.16--69.70\*1.970.0000.81--4.804 (4)4.570.2230.4--52.561.100.8690.37--3.29 Vomiting66 (4)8 (9)\*2.520.0231.13--5.6330 (33)5.440.0002.60--11.4012.250.0006.42--23.407 (8)0.860.7650.33--2.281.600.3150.64--4.04*C*. *parvum* Dizziness106 (6)16 (7)1.330.4020.69--2.5658 (27)5.100.0002.97--8.757.670.0004.70--12.5232 (15)2.250.0011.39--3.663.090.0001.78--5.36 Headache359 (20)31 (14)0.510.0050.32--0.8175 (35)3.480.0002.28--5.311.680.0071.15--2.4356 (26)2.190.0001.54--3.131.110.6130.75--1.65 Joint pain516 (29)26 (12)0.750.2650.45--1.2550 (23)2.320.0011.43--3.751.720.0131.12--2.6438 (18)1.600.0231.07--2.391.190.4540.75--1.88 Fatigue51 (3)74 (34)1.210.2960.85--1.71172 (80)7.950.0005.22--12.1010.850.0007.34--16.06110 (51)2.030.0001.51--2.702.600.0001.86--3.65 Weight loss60 (3)28 (13)5.140.0002.78--9.49142 (66)13.700.0008.33--22.5271.990.00042.72--121.3439 (18)1.490.0950.93--2.387.800.0004.38--13.87 Diarrhoea242 (14)63 (29)25.220.00013.86--45.9188 (87)17.080.00010.33--28.24521.450.000248.9--1092.583 (38)1.530.0161.08--2.1640.550.00022.47--73.19 Loss of appetite432 (24)48 (22)2.230.0001.48--3.37172 (80)17.890.00010.09--28.8638.260.00024.24--60.3955 (25)1.220.3800.78--1.912.700.0001.80--4.05 Abdominal pain225 (13)65 (30)1.530.0241.06--2.22172 (80)10.430.0006.67--16.3018.050.00011.83--27.5376 (35)1.280.1450.92--1.781.960.0001.37--2.81 Eye pain110 (6)10 (5)1.020.9610.48--2.1723 (11)2.680.0111.25--5.762.380.0031.34--4.2515 (7)1.590.1640.83--3.081.480.2430.77--2.87 Vomiting66 (4)17 (8)2.660.0041.37--5.1670 (32)5.930.0003.31--10.6616.660.00010.08--27.5414 (6)0.810.5650.39--1.672.300.0211.14--4.65Number (*n*) of cases or controls and percentage of the total number of cases (*C*. *hominis* = 92 and *C*. *parvum* = 216) or controls (*n* = 1790) reporting each symptom. Odds ratios (aOR) and corresponding 95% confidence intervals (CI) are adjusted for age, gender, study year and season\*No longer statistically significant when removing children under 5 years of age from the analysis: weight loss before *C*. *hominis* infection vs. controls OR 4.95 (95% CI 0.90--10.18, *p* = 0.073), vomiting before *C*. *hominis* infection vs. controls OR 2.83 (95% CI 0.90--8.89, *p* = 0.074), eye pain during *C*. *hominis* infection vs. controls OR 2.15 (95% CI 0.81--5.69, *p* = 0.125)Table 4Comparisons of symptom occurrence among cases 4 months before, during and 4 months after infection with *C*. *hominis* vs. *C*. *parvum*SymptomsBefore illnessDuring illnessAfter illness*C*. *hominisC*. *parvum*aOR*p*95% CI*C*. *hominisC*. *parvum*aOR*p*95% CI*C*. *hominisC*. *parvum*aOR*p*95% CI*n* (%)*n* (%)*n* (%)*n* (%)*n* (%)*n* (%)Dizziness7 (8)16 (7)0.560.2970.19--1.6522 (24)58 (27)\*0.480.0630.22--1.0313 (14)32 (15)0.610.2770.25--1.49Headache13 (14)31 (14)0.770.5500.33--1.8131 (34)75 (35)0.700.2920.36--1.3622 (24)56 (26)0.840.6300.41--1.72Joint pain6 (7)26 (12)0.990.9930.34--2.9113 (14)50 (23)0.870.7340.38--1.9714 (15)38 (18)1.050.9020.46--2.39Fatigue31 (34)74 (34)0.850.6060.45--1.5967 (73)172 (80)0.990.9870.48--2.0646 (50)110 (51)0.920.7780.51--1.65Weight loss9 (10)28 (13)1.850.2050.71--4.7754 (59)142 (66)1.350.3490.71--2.5222 (24)39 (18)0.950.8840.45--1.97Diarrhoea38 (41)63 (29)0.800.4920.43--1.5081 (88)188 (87)1.100.8340.44--2.7846 (50)83 (38)0.830.5380.45--1.51Loss of appetite25 (27)48 (22)1.130.7280.56--2.2776 (83)172 (80)1.120.7680.52--2.4436 (39)55 (26)0.840.5960.43--1.62Abdominal pain32 (35)65 (30)1.040.9180.53--2.0273 (79)172 (80)0.860.7000.40--1.8542 (46)76 (35)0.620.1280.34--1.14Eye pain1 (1)10 (5)1.000.9930.11--8.867 (8)23 (11)1.200.7370.41--3.544 (4)15 (7)1.090.8990.28--4.25Vomiting8 (9)17 (8)1.020.9750.34--3.0330 (33)70 (32)1.340.3750.70--2.547 (8)14 (7)2.210.1790.69--7.00Number (*n*) of cases and percentage of the total number of cases (*C*. *hominis* = 92 and *C*. *parvum* = 216) reporting each symptom. Odds ratios (aOR) and corresponding 95% confidence intervals (CI) are adjusted for age, gender, study year and season\*Statistically significant when removing children under 5 years of age from the analysis (OR 0.43, 95% CI 0.19--0.95, *p* = 0.038)

When removing children under 5 years of age from the analysis, there were no major differences in the results, with only a few exceptions indicated in the footnotes of Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, and [4](#Tab4){ref-type="table"}.

Discussion {#Sec7}
==========

In line with previous studies \[[@CR13]--[@CR16]\], our data showed that an acute episode of cryptosporidiosis is associated with long-term sequelae. Indeed, 4 months after diagnosis of cryptosporidiosis, several gastrointestinal and non-gastrointestinal symptoms were still occurring at a higher frequency as compared to the period before the onset of acute illness and to the general population (controls). The odds of having non-gastrointestinal symptoms as sequelae were generally higher than those having gastrointestinal symptoms. Yet, when symptom occurrence among cases after illness was compared to the population controls, it appeared that gastrointestinal sequelae were those occurring significantly more often, and that sequelae like joint pain (which occurred significantly more often among cases after illness as compared to before illness) occurred after illness at a rate that was not significantly different from that observed in the general population. At the analysis of the two species separately, results agree with the overall analysis to a major extent, although it is generally more difficult to draw conclusions due to the low numbers of cases. However, the comparison among cases (*C*. *hominis* vs. *C*. *parvum*) clearly showed that there are no significant differences of one *Cryptosporidium* species causing significantly more gastrointestinal (and the other one more non-gastrointestinal) sequelae, as originally hypothesised. Indeed, one of the studies describing sequelae following cryptosporidiosis \[[@CR16]\] found that recurrent gastrointestinal symptoms occurred regardless of species, but not the non-gastrointestinal ones (e.g. joint pain, eye pain, headache, dizziness and fatigue). These symptoms were common in cases with *C*. *hominis* infection, but not in those infected with *C*. *parvum*. The other study found no difference in frequency of persisting symptoms between patients infected with *C*. *parvum* or *C*. *homini* \[[@CR15]\]. In this regard, our results show a more homogeneous picture with no clear separation of symptoms between the two species. The other two studies investigating sequelae reported information only on either *C*. *hominis* \[[@CR14]\] or *C*. *parvum* \[[@CR13]\], but not the two together, and both gastrointestinal and non-gastrointestinal symptoms were found to be associated with infection.

The age and gender distribution of the cases was in line with the one expected, as generally younger and middle-aged groups are most affected by *Cryptosporidium* infection. The explanation for the 26--50-year-old age group being particularly affected by diseases like cryptosporidiosis is that this age group often contains parents and child-carers, which are predominantly females, which are thus more likely to be exposed to *Cryptosporidium* from the children themselves \[[@CR22]\]. In our study, cryptosporidiosis in older age groups was also prevalent, as reported before \[[@CR23]\].

The frequency of some symptoms during and after the illness shows the natural course of the disease, e.g. loss of appetite and vomiting were very likely to occur during the acute phase of the illness, but much less so afterwards. The same is true for non-gastrointestinal symptoms like joint pain, eye pain and headache which were very prevalent during the infection as a direct consequence of the acute infection itself, for example as a consequence of fever and malaise. However, the number of people still experiencing symptoms of, e.g. diarrhoea, fatigue, dizziness and weight loss in the follow-up is striking. The finding that some symptoms occurred more frequently among cases even *before* illness as compared to what is observed in the population controls might be a sign that people acquiring cryptosporidiosis may be a particular group of the population with a generally increased susceptibility to (gastrointestinal) illness per se (e.g. people with underlying chronic conditions), which may also entail an increased likelihood of being diagnosed with cryptosporidiosis due to enhanced medical scrutiny for these patients, as shown for other pathogens \[[@CR24], [@CR25]\]. Indeed, high proportions of cases reporting a given symptom after illness had also reported the same symptom before illness (i.e. dizziness 36%, headache 45%, fatigue 54%, weight loss 28%, diarrhoea 50%, loss of appetite 42%, abdominal pain 53%, joint pain 42%, eye pain 32%, vomiting 19%). Results may have also been influenced by substantial recall bias, regarding the symptoms for the period before infection and symptoms occurring after the acute phase were over. Moreover, cases are probably more self-aware due to the initial infection and therefore more prone to remember symptoms after diagnosis. Although there is complete control of between-person confounders, another key limitation of this study design is in the control of within-person confounding, which is still possible for multiple, correlated transient factors that change over time within a subject, such as symptoms related to another acquired illness or injury. Moreover, selection bias may have been introduced by cases being particularly motivated to participate in the follow-up study because of the presence of sequelae. Finally, because the follow-up questionnaire did not emphasise the "chronicity" of sequelae, it was not possible to assess whether symptoms occurred once or several times over the 4-month period after illness.

In conclusion, this study adds to the growing body of evidence for the presence of sequelae following cryptosporidiosis, so far represented by four published studies. While some studies have observed species-specific effects on sequelae, we did not see a clear differentiation between sequelae and the infecting *Cryptosporidium* species. However, subtype information was not available, and there are studies indicating that some subtypes within the same genotype can manifest in different ways and might be more virulent than others \[[@CR26]\], which could be interesting to address in future investigations. Although our results do not change the general advice for patient care, awareness of medical personnel should be raised that non-gastrointestinal symptoms can be the consequence of enteric infection. As there is no treatment for cryptosporidiosis, the focus should be on preventive measures.
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